Want to see SE:IMMNOV full AI Analyst Report?
Immunovia AB (IMMNOV) AI Stock Analysis
Immunovia AB
(Nasdaq OMX AB:IMMNOV)
Weak financial performance with persistent losses and cash burn is the primary drag, partially offset by positive earnings call developments on test adoption and extended runway; bearish technicals and negative valuation metrics add further pressure.
Immunovia AB (IMMNOV) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 6.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 5.36M
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.97
- Revenue Growth
- 31.66%
- EPS Growth
- 79.68%
- Country
- Sweden
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Immunovia AB Business Overview & Revenue Model
Company Description
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic...
Immunovia AB Earnings Call Summary
The call was predominantly positive, with strong year-over-year revenue growth, accelerating PancreaSure adoption, progress toward reimbursement, lower operating losses and cash burn below prior guidance. These developments were offset by continued operating losses, limited reimbursement data, uncertain coverage timing, the absence of sales guidance and a highly dilutive rights issue required to fund operations into 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said Q3 cash burn was SEK 5 million per month, significantly below the previously discussed guidance of SEK 8 million to SEK 10 million per month; the rights issue is expected to raise approximately SEK 63 million before issue costs and compensation to the underwriters, with 80% secured, or approximately SEK 50 million, to fund operations through the second quarter of 2027, while TO 4 could potentially generate additional proceeds of SEK 31.7 million to fund operations into the third quarter 2027. The subscription period is November 9 to November 25 this year, and the warrant subscription period is April 19 to May 3, 2027. The company does not give sales guidance for 2026, expects to share preliminary insurance-payment data with potential U.S. commercialization partners in the fourth quarter, expects to talk to FDA again early in 2027, and is expanding PancreaSure to the other 2 dozen clinicians at SSGA.
Immunovia AB Financial Statement Overview
Summary
Persistent deep losses, negative gross margins, sharply declining equity and assets, and ongoing cash burn outweigh modest TTM revenue growth and low debt levels.
Income Statement
15Very NegativeBalance Sheet
10Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.21M | 685.00K | 931.00K | 1.57M | 1.15M | 844.00K |
| Gross Profit | -15.85M | -79.50M | 931.00K | -5.11M | -3.07M | 15.81M |
| EBITDA | -79.94M | -77.18M | -61.27M | -166.56M | -141.58M | -135.47M |
| Net Income | -88.33M | -145.91M | -76.54M | -309.44M | -145.03M | -157.40M |
Balance Sheet | ||||||
| Total Assets | 48.03M | 88.21M | 33.04M | 98.68M | 300.59M | 493.81M |
| Cash, Cash Equivalents and Short-Term Investments | 34.90M | 77.46M | 25.32M | 76.79M | 106.04M | 287.41M |
| Total Debt | 3.27M | 857.00K | 680.00K | 4.29M | 37.57M | 33.26M |
| Total Liabilities | 24.40M | 23.48M | 21.39M | 31.69M | 56.79M | 59.91M |
| Stockholders Equity | 23.64M | 64.73M | 11.65M | 66.99M | 243.80M | 433.90M |
Cash Flow | ||||||
| Free Cash Flow | -82.91M | -78.40M | -96.75M | -148.12M | -177.21M | -176.83M |
| Operating Cash Flow | -77.35M | -78.40M | -96.75M | -147.06M | -175.58M | -152.65M |
| Investing Cash Flow | -5.69M | -5.69M | 0 | 3.20M | -1.62M | -23.83M |
| Financing Cash Flow | 89.15M | 136.82M | 44.81M | 114.74M | -5.11M | -5.27M |
Immunovia AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMNOV, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.11, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 30.34 is Neutral, neither overbought nor oversold. The STOCH value of 12.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IMMNOV.
Immunovia AB Peers Comparison
Overall Rating
SE:DVYSR62Neutral- SE:IMMNOV48Neutral
SE:QLINEA43Neutral
SE:ACARIX40Underperform
SE:BIOVIC.B37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:DVYSR | 62Neutral | SEK 928.94M | 59.78 | ― | ― | 6.51% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:IMMNOV | 48Neutral | SEK 33.70M | -0.30 | -279.07% | ― | 31.66% | 79.68% |
| SE:QLINEA | 43Neutral | SEK 282.34M | -1.13 | -48.10% | ― | 33.26% | 90.73% |
| SE:ACARIX | 40Underperform | SEK 223.04M | -5.29 | -100.09% | ― | 65.82% | 41.28% |
| SE:BIOVIC.B | 37Underperform | SEK 103.68M | -1.44 | -75.51% | ― | 56.06% | 63.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:IMMNOV | Immunovia AB | 0.05 | -0.26 | -83.92% | |
| SE:QLINEA | Q-linea AB | 14.90 | -10.33 | -40.94% | |
| SE:ACARIX | Acarix AB | 0.18 | -0.09 | -32.96% | |
| SE:BIOVIC.B | Biovica International AB Class B | 0.36 | -0.13 | -27.03% | |
| SE:DVYSR | Devyser Diagnostics AB | 55.00 | -69.00 | -55.65% |
Immunovia AB Corporate Events
Immunovia Reports Stronger PancreaSure Sales in Third Quarter
Immunovia reported third-quarter 2026 net sales of SEK 843,000, up from SEK 101,000 a year earlier, as PancreaSure sales and royalty income increased. The operating loss narrowed to SEK 17.7 million from SEK 25.1 million, while operating cash flow im...
Immunovia Sets Q3 2026 Report Release and Investor Webcast
Pancreatic cancer diagnostics company Immunovia AB will release its interim report for the third quarter of 2026 on November 2 at 15:00 CET. The Nasdaq Stockholm-listed firm is inviting investors and other stakeholders to a webcast presentation the s...
Immunovia Secures Shareholder Backing for Major Rights Issue and Capital Structure Changes
Immunovia AB held an extraordinary general meeting on 29 October 2026, where shareholders approved changes to the company’s Articles of Association to adjust limits on share capital and the number of shares, in line with a planned rights issue....
Immunovia Sets Final Terms for Discounted Rights Issue to Fund PancreaSure Push
Immunovia AB has set the final terms for a rights issue of up to 1,057,047,973 units, each comprising two shares and one warrant, at a subscription price of SEK 0.06 per unit. The pricing reflects a discount of about 25 percent to the theoretical ex-...
Immunovia Builds Case for PancreaSure in Hereditary High-Risk Pancreatic Cancer Market
Immunovia AB has published peer-reviewed data showing its PancreaSure blood test delivers 77.5% sensitivity and 93.6% specificity in detecting early-stage pancreatic ductal adenocarcinoma among individuals with inherited genetic mutations or a famili...
Immunovia Launches SEK 63 Million Rights Issue to Fund PancreaSure Push
Immunovia plans a rights issue of units, comprising shares and warrants, to initially raise about SEK 63 million, with roughly 80 percent backed by subscription undertakings and guarantee commitments. The financing will support continued U.S. commerc...
Immunovia Calls Extraordinary Meeting to Enable Flexible Rights Issue
Immunovia AB has called an Extraordinary General Meeting in Lund on 29 October 2026, inviting shareholders of record by 21 October to vote in person or by proxy on several key governance and financing measures. The agenda includes changes to the Arti...
Immunovia Seeks Medicare Coverage for PancreaSure Pancreatic Cancer Test
Immunovia AB has taken a significant regulatory step by submitting a formal request for a new Local Coverage Determination for its PancreaSure blood test, seeking Medicare coverage for early detection of pancreatic cancer in high-risk individuals. Th...
Immunovia Survey Shows Strong Demand for Blood-Based Pancreatic Cancer Tests
Immunovia AB, listed on Nasdaq Stockholm, specializes in blood-based diagnostics for early detection of pancreatic cancer in high-risk individuals. The company collaborates with healthcare providers, experts and patient advocacy groups to expand acce...
Immunovia boosts PancreaSure uptake as clinical evidence builds and cash burn stays below guidance
Immunovia AB reported second-quarter 2026 net sales of 381 KSEK, driven mainly by PancreaSure testing, while operating losses widened to 22.8 MSEK, though cash burn stayed below guidance and liquidity improved to 34.9 MSEK. PancreaSure adoption accel...
Immunovia to Present Q2 2026 Report Amid Push in Pancreatic Cancer Diagnostics
Immunovia AB, a Nasdaq Stockholm-listed diagnostics specialist, focuses on blood-based tests for early detection of pancreatic cancer and collaborates with healthcare providers and advocacy groups to reach high-risk individuals, especially in the lar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026